Cibus, Inc.

NASDAQ:CBUS

Biotechnology

Healthcare
$1.37 +3.10%

+$0.04 today

Market cap
$104.71M
Beta
1.65
P/E (TTM)
-8.6
EPS (TTM)
-$0.16
52W Low $1.09High $4.19

Volume 0.25M

Average 0.51M

CBUS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Cibus, Inc.NASDAQ: CBUS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 28.8%

Gross margin was 28.8% in Q1 FY2026, down 71.2 pp from a year earlier. On a trailing-twelve-month basis it was 72.1%, up 8.5 pp year over year. Over 3 fiscal years it widened by 814.3 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
28.8%-71.2 pp QoQ
Last fiscal yearDec 2025
-62.8%-162.8 pp YoY
LTMMar 2026
72.1%+8.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-71.2 pp——
1 year-162.8 pp——
3 years+814.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-62.8%
Year-over-year change
-162.8pp

Gross Margin vs competitors

How CBUS compares with its peers on the latest reported figures

  • CBUS's LTM Mar 2026 gross margin of 72.1% is the 3rd highest of the 4 companies compared; the peer median is 76.2%.
  • Its year-over-year change of +8.5 pp is the 2nd highest of 3, against a peer median of +15.4 pp.
  • Over three fiscal years its change of +814.3 pp compares with a peer median of +0.0 pp.
CBUS Competitors Peer median
Gross Margin for CBUS and competitors
Company Period LTM level YoY 3-year change
VXRTVaxart, Inc.LTM Mar 2026100.0% +0.0 pp+0.0 pp
CAMPCAMP4 Therapeutics CorporationLTM Mar 202676.2% +30.8 pp—
CBUSCibus, Inc.LTM Mar 202672.1% +8.5 pp+814.3 pp
MNOVMediciNova, Inc.LTM Mar 202615.2% ——
RLMDRelmada Therapeutics, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
UNCYUnicycive Therapeutics, Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
Peer median (excluding CBUS) 76.2%+15.4 pp+0.0 pp

Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.99M157K1.82M4.26M3.64M
Cost of Revenue28.56M1.53M395K05.92M
Gross Profit(2.57M)(1.38M)1.42M4.26M(2.28M)
Gross Margin-9.9%-877.1%78.3%100.0%-62.8%
Research & Development11.34M11.55M42.37M50.43M44.2M
Selling, General & Admin15.38M9.44M28.91M30.8M26.91M
Operating Expenses26.76M20.99M320.31M262.66M65.18M
Depreciation & Amortization2.34M1.53M4.69M6.86M5.92M
EBITDA(25.43M)(15.21M)(314.59M)(241.64M)(90.77M)
EBITDA Margin-97.9%-9687.9%-17313.4%-5669.5%-2494.3%
Operating Income(29.33M)(22.37M)(318.88M)(258.4M)(67.46M)
Operating Margin-112.9%-14248.4%-17550.0%-6062.8%-1853.9%
Interest Income17K60K527K631K438K
Interest Expense1.43M87K18.89M34.19M35.48M
Other Income / Expenses133K5.48M(18.76M)(24.29M)(64.71M)
Income Before Tax(29.2M)(16.89M)(337.64M)(282.68M)(132.17M)
Pre-Tax Margin-112.4%-10758.6%-18582.4%-6632.7%-3632.1%
Income Tax Expense00(4K)29K29K
Net Income(29.2M)(16.89M)(267.63M)(251.39M)(127.09M)
Net Margin-112.4%-10758.6%-14729.1%-5898.4%-3492.3%
EPS (Basic)(0.05)(0.03)(25.95)(10.83)(2.78)
EPS (Diluted)(0.05)(0.03)(25.95)(10.83)(2.78)
Weighted Avg Shares578.47M578.47M10.31M23.22M457.57M
Weighted Avg Shares (Diluted)578.47M578.47M10.31M23.22M457.57M

Cibus, Inc.

NASDAQ:CBUS

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.